Effectiveness in Real Life of the Insulia® Digital Tool in Patients with Type 2 Diabetes Treated with Basal Insulin Therapy As Part of a National Telemedicine Program (ETAPES)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- HbA1c
研究概览
简要总结
The purpose of this study was to evaluate the INSULIA digital tool (automation of basal insulin dose calculation in type 2 diabetes) within the framework of a French national telemedicine experimentation program (ETAPES) in a single-center study.
The assumption is that a better metabolic control with this tool.
详细描述
Basal insulin titration in people with type 2 diabetes is of major importance to obtain the optimal dose to regulate fasting blood glucose without hypoglycemia.
Significant inertia in treatment optimization has been observed among both general practitioners and diabetologists.
The INSULIA tool (automation of basal insulin dose calculation in type 2 diabetes) within the framework of a French national telemedicine experimentation program (ETAPES) has been supported by the health authorities.
The data collected are of a single-center cohort of adult patients with type 2 diabetes who used this tool between 2018 and 2021.
It is supposed that a better metabolic control with this tool and aimed to understand factors associated with better results.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old.
- •Patients with type 2 diabetes.
- •Initiation or adjustment of basal insulin.
- •Prescription of Insulia® for more than 6 months (between august 2018 and june 2021)
- •Informed patient not opposed to the research
排除标准
- •Patient opposed to the research
结局指标
主要结局
HbA1c
时间窗: at 6 months
Evolution of HbA1c between baseline and 6 months after Insulia initiation
次要结局
- HbA1c objective(at 6 months)
- Insulin(at 6 months)
- Mean fasting glucose(at 6 months)